Glenmark Pharma shares in focus after FDA grants fast track status to cancer drug
shares will be in focus on Tuesday after the company announced that its innovation arm, Ichnos Glenmark Innovation (IGI), has received 'fast track' designation from the US Food and Drug Administration (FDA) for its investigational therapy ISB 2001.
The designation applies to adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of treatment, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
ISB 2001 is a tri-specific antibody therapeutic designed to target BCMA and CD38 on myeloma cells, as well as CD3 on T cells, enabling a targeted immune response against cancer. The therapy is currently being evaluated in a Phase 1 dose expansion clinical study.
Play Video
Pause
Skip Backward
Skip Forward
Unmute
Current Time
0:00
/
Duration
0:00
Loaded
:
0%
0:00
Stream Type
LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
1x
Playback Rate
Chapters
Chapters
Descriptions
descriptions off
, selected
Captions
captions settings
, opens captions settings dialog
captions off
, selected
Audio Track
default
, selected
Picture-in-Picture
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text
Color
White
Black
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Text Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Transparent
Caption Area Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Transparent
Semi-Transparent
Opaque
Font Size
50%
75%
100%
125%
150%
175%
200%
300%
400%
Text Edge Style
None
Raised
Depressed
Uniform
Drop shadow
Font Family
Proportional Sans-Serif
Monospace Sans-Serif
Proportional Serif
Monospace Serif
Casual
Script
Small Caps
Reset
restore all settings to the default values
Done
Close Modal Dialog
End of dialog window.
Ichnos Glenmark Innovation recently completed the dose escalation portion of its Phase 1 clinical trial in patients with heavily pre-treated multiple myeloma.
Initial results from the study, presented during an oral session at the American Society of Hematology (ASH) Annual Meeting in December 2024, demonstrated a high overall response rate (ORR), durable responses, and a favorable safety profile.
Live Events
Complete results from the dose escalation portion will be presented in a rapid oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 2, 2025.
The FDA's fast track designation is intended to facilitate the development and accelerate the review of drugs that treat serious conditions and address unmet medical needs, with the goal of making important new treatments available to patients sooner.
A drug granted fast track status may be eligible for more frequent meetings and communications with the FDA, as well as rolling review of any marketing application.
It may also qualify for priority review if certain criteria are met. Notably, ISB 2001 was previously granted 'orphan drug' designation by the FDA in July 2023.
Also Read:
8 Nifty Microcap stocks that can jump 100-230% in the next 12 months
Glenmark Pharma: Price Target
According to Trendlyne data, the average target price for the stock is Rs 1,691, indicating an upside of 20% from current levels. The consensus recommendation from 12 analysts is a 'Buy'.
Also Read:
5 timeless Warren Buffett quotes every investor should know
Glenmark Pharma: Share price performance
On Monday,
Glenmark Pharma shares
closed 2.2% higher at Rs 1,405.7 on the BSE, while the benchmark Sensex rose 0.37%. The stock has declined 13% year-to-date but has surged 155% over the past two years. Its current market capitalisation stands at Rs 39,670 crore.
Also Read:
SBI, LIC among 10 large-cap stocks that are below industry PE levels can rally up to 32%
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
11 hours ago
- News18
Ousted FDA vaccine chief Vinay Prasad returning to agency
Washington, Aug 11 (AP) A Food and Drug Administration official is getting his job back as the agency's top vaccine regulator, less than two weeks after he was pressured to step down at the urging of biotech executives, patient groups and conservative allies of President Donald Trump. Dr Vinay Prasad is resuming leadership of the FDA centre that regulates vaccines and biotech therapies, a spokesperson for the Department of Health and Human Services said in a statement Monday. Prasad left the agency late last month after drawing ire of right-wing activists, including Laura Loomer, because of his past statements criticizing Trump. A longtime a critic of FDA's standards for approving medicines, Prasad briefly ordered the maker of a gene therapy for Duchenne's muscular dystrophy to halt shipments after two patient deaths. But that action triggered pushback from the families of boys with the fatal condition and libertarian supporters of increased access to experimental medicines. Prasad's decision to pause the therapy was criticized by The Wall Street Journal editorial board, former Republican Sen Rick Santorum and others. The FDA swiftly reversed its decision suspending the therapy's use. Loomer posted online that Prasad was 'a progressive leftist saboteur," noting his history of praising liberal independent Sen. Bernie Sanders. But Prasad has had the backing of FDA Commissioner Marty Makary and health secretary Robert F Kennedy Jr, who have both called for scrutinizing the use of COVID-19 vaccines. Under Prasad, the FDA restricted the approval of two new COVID-19 shots from vaccine makers Novavax and Moderna and set stricter testing requirements for future approvals. (AP) RD RD view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hindustan Times
12 hours ago
- Hindustan Times
America's drug regulator is in turmoil
TO APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, consider the recent rollercoaster ride of Sarepta Therapeutics, a biotech firm. In 2023 the FDA granted accelerated approval for its gene therapy for Duchenne muscular dystrophy, a rare genetic disorder that typically causes death in early adulthood. Peter Marks, director of the FDA's biologics centre at the time, approved the treatment despite reviewers' concerns about limited clinical data. Some hailed that as proof the FDA could be nimble in cases where sufferers had few options. The treatment costs an eye-watering $3.2m per patient, so the drug's approval delivered Sarepta a major payday. But in the past four months three patients on Sarepta's treatments have died from acute liver failure. On July 18th the FDA asked the firm to suspend distribution. Within days its stock lost nearly half of its value (see chart 1). Illustration: Vartika Sharma Chart 1 Political drama followed. Laura Loomer, a conspiracy theorist with access to President Donald Trump, accused Vinay Prasad—Dr Marks' successor and a long-standing critic of loosening evidentiary standards for drug approvals—of being a 'leftist saboteur' bent on derailing 'Trump's deregulatory mission'. Her attack was widely seen as criticism of his decision to pause Sarepta's therapy. On July 28th the FDA reauthorised the treatment's use for some younger patients. By the next day Dr Prasad had resigned to 'spend more time with his family'. George Tidmarsh, a physician-scientist newly in charge of the agency's other key drug-evaluation division, became acting head of this one, too. But on August 9th Dr Prasad was re-hired, apparently after being persuaded that the FDA's commissioner, Martin Makary, supported him. Ms Loomer responded by threatening exposés of FDA officials. It is hardly a picture of stable decision-making at an agency responsible for regulating products that account for some 14% of America's GDP. Drugs that target rare diseases, known as orphan drugs, constitute a distinctive segment of the pharmaceutical industry, one that is replete with extraordinary financial promise, scientific risk and knotty ethical considerations. The FDA polices this frontier. It is a treacherous mandate even without interventions by the likes of Ms Loomer. And while the challenges for rare-disease drugs are especially acute, they mirror those facing the entire sector in a regulatory landscape for drugs and new treatments that is growing ever more politicised and unstable. Though 200m-500m people worldwide suffer from rare diseases—and nearly half of these illnesses affect children—drugmakers had long neglected the development of treatments. To spur such work Congress passed the Orphan Drug Act in 1983. It offers companies seven years of market exclusivity. Between the legislation's strong incentives and advances in cell and gene therapies, orphan drugs have become an important sector for biotech firms. Today these therapies account for roughly half of the new drugs the FDA approves. They are lucrative, too. Some companies, such as Sarepta, rely almost entirely on orphan drugs for their revenue. Even Johnson & Johnson, a pharmaceutical giant, earned roughly a third of its revenue from these treatments in 2024, according to Evaluate, a pharmaceutical-analytics firm (see chart 2). Mr Makary, the new commissioner of the FDA, has joined a long line of agency chiefs in calling for faster drug reviews, which can take ten months. In June the FDA launched a pilot scheme to cut that to just a month or two for treatments deemed to support 'national interests'. Because robust randomised trials are often unfeasible for rare diseases given the tiny patient pool, Mr Makary has also talked about developing quicker alternative approval pathways for orphan drugs. But these moves towards innovation have been undermined by the administration's inclination to shoot first and aim later. Speaking on the Megyn Kelly Show, a podcast, Mr Makary announced a plan to speed up drug approvals for ultra-rare diseases by relying on 'a plausible mechanism', meaning a scientific explanation showing that treatments could theoretically lead to improved outcomes. Such a standard would be 'about as low as it goes', argues Daniel Kracov, a lawyer who advises pharmaceutical firms on regulation. However, parents of patients with diseases so rare that they can be impossible to run trials for are pushing for new ways to win approval for novel drugs. Officials at the FDA worry that the push to accelerate approvals without hiring more staff will backfire. One reviewer who works on rare diseases notes that during evaluations of proposed treatments for them, the science can be less familiar, the clinical trials smaller, and approval may hinge on less conventional intermediate evidence. This uncertainty can breed scepticism initially. What often persuades reviewers of a treatment's safety and efficacy is statistical stress-testing and other scrutiny of the evidence that can take months. Speeding this up risks causing reviewers to err on the side of caution, which could lead to fewer approvals, not more. Side effects may include Congress is another source of uncertainty. Lawmakers have so far failed to reauthorise a voucher programme that encouraged drugmakers to pursue treatments for rare pediatric diseases. In exchange, companies received a voucher granting expedited FDA review for another drug. The vouchers are transferable and can be sold for tens of millions of dollars on a secondary market (see chart 3). Amid instability, 'vouchers are selling for more, because there is some possibility that Congress will not get this done by the end of 2026', says David Ridley, a health economist at Duke University. Drug development typically takes a decade or longer, which is why investors prize policy certainty. 'The biggest thing is, you want the FDA to be consistent,' explains Matt Phipps, a biotech analyst at William Blair, an investment bank. 'You want them to tell you something and then stick with it and not change their minds at the last minute.' Smaller biotech firms that fuel early innovation across the industry will struggle most to ride out the volatility. Funding cuts at the National Institutes of Health, the wellspring of biomedical research, and threats of pharmaceutical tariffs have given a hypersensitive industry additional reasons to retreat. More uncertainty at the FDA is likely to make it harder to approve drugs in general, and possibly orphan drugs especially. Rollercoasters are no fun when you have no choice but to ride them. America-s-drug-regulator-is-in-turmoil
Hindustan Times
13 hours ago
- Hindustan Times
What is kava? Major warnings issued on TikTok about ‘Feel Free' drinks amid kratom products ban in Louisiana
Experts and social media users are alerting the public about 'Feel Free' tonics and other items that include kratom, a chemical that resembles opioids, as per NBC News. Feel Free drinks are supplied in two-ounce containers. A serving size is one ounce, according to the label, and consumers should not take more than two ounces in a 24-hour period, according to NBC News. (X@KJovian) This comes as FDA warns that products made from kratom, a plant found in Southeast Asia, are becoming more common in gas stations, corner stores, and vape shops countrywide. The drug is frequently used to 'self-treat conditions such as pain, coughing, diarrhea, anxiety and depression, opioid use disorder, and opioid withdrawal,' the FDA stated. University of Minnesota Medical School addiction medicine specialist Dr. Robert Levy told NBC News that he has "many times" handled patients who became addicted to kratom. Also Read: Kratom rise sparks concerns over addiction amid RFK Jr's 7-OH crackdown; What is it and how it impacts your health What is kava or kratom? Although kava and/or kratom-based drinks have been promoted as mood enhancers and energy boosters, some customers claim that the items are causing addiction. If kava is used frequently to treat anxiety, stress, or sleep issues, people may become psychologically dependent on it. According to Crestview Recovery, this might result in increased tolerance, minor withdrawal symptoms, compulsive usage, responsibility neglect, and trouble cutting back on use. Warnings spread on TikTok about 'Feel Free' drinks Last month, TikToker Misha Brown shared a video that went viral, showing how a child approached him at a petrol station and requested him to buy a Feel Free tonic, a kratom-containing beverage. Brown claimed that after he declined, the boy attempted to take his wallet but was unsuccessful in his attempt. The clerk at the gas station then informed Brown that she frequently witnesses the same consumers purchasing the same beverage several times throughout the day. 'It's so addictive, and people lose their minds,' Brown claimed the cashier informed him. Speaking about the viral video, Brown told NBC News, individuals started sharing their own 'devastating experiences' after using kratom products like Feel Free. John, a TikToker who has shared content on Feel Free after battling with heroin and meth addictions, claimed to have found the tonic when he was eight years sober. NBC News John in a bid to preserve his identity. John admitted to the source that he developed an addiction and started devouring entire Feel Free cases in a single day. In February, he was admitted to the hospital for severe withdrawal symptoms as he attempted to stop using Feel Free. Feel Free tonics are supplied in two-ounce containers. A serving size is one ounce, according to the label, and consumers should not take more than two ounces in a 24-hour period, according to NBC News. In addition, the label cautions that the product can lead to habit formation and suggests that people who have previously abused substances should think twice before using it. Here's what Botanic Tonics said Botanic Tonics, the company that produces Feel Free, said in a statement to The Independent that the NBC News piece featured "false and misleading statements" and that they had not received any complaints about serious addiction. Earlier, Botanic Tonics settled a class action lawsuit alleging the firm failed to alert users about the risks of kratom in 2023 for $8.75 million. The company settled the claim without acknowledging any wrongdoing. Ban on kratom products in Louisiana. Are items made from kava prohibited in the state? The Louisiana House of Representatives approved Senate Bill 154 (SB154), which would outlaw the distribution and possession of kratom. The House cleared SB154 by a vote of 87 to 6. Since the Senate has already approved the bill, it now needs to be signed into law by Governor Jeff Landry. SB154 would designate mitragynine and 7-hydroxymitragynine as Schedule 1 drugs, which are chemicals that are currently not approved for use in medicine in the United States and are thought to have a high potential for misuse. According to the bill, it would also make it illegal to produce, distribute, or possess kratom. Although Louisiana has implemented laws pertaining to the distribution and possession of kratom, the state has not outlawed the sale of kava products. Nonetheless, several parishes have imposed local prohibitions, and state-level rules have been put into effect.
